[{"id":"dfb4196c-a977-4285-8b52-26ba36ee3448","acronym":"","url":"https://clinicaltrials.gov/study/NCT07476287","created_at":"2026-03-28T01:40:30.305Z","updated_at":"2026-03-28T01:40:30.305Z","phase":"Phase 2","brief_title":"Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer","source_id_and_acronym":"NCT07476287","lead_sponsor":"Pfizer","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/15/2026","start_date":" 05/15/2026","primary_txt":" Primary completion: 03/19/2028","primary_completion_date":" 03/19/2028","study_txt":" Completion: 03/19/2031","study_completion_date":" 03/19/2031","last_update_posted":"2026-03-17"},{"id":"ce020719-ee60-4c78-aac1-c9da91de0268","acronym":"GIVEN","url":"https://clinicaltrials.gov/study/NCT07472478","created_at":"2026-03-28T01:39:49.899Z","updated_at":"2026-03-28T01:39:49.899Z","phase":"Phase 2","brief_title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","source_id_and_acronym":"NCT07472478 - GIVEN","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Anfangning (garsorasib) • Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/15/2026","start_date":" 03/15/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2026-03-16"},{"id":"b0107240-c9ff-4b67-b853-211b0d9cdc8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07469774","created_at":"2026-03-28T01:44:13.768Z","updated_at":"2026-03-28T01:44:13.768Z","phase":"Phase 1/2","brief_title":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07469774","lead_sponsor":"Biocity Biopharmaceutics Co., Ltd.","biomarkers":" EGFR • BRAF • ALK • MET • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • BRAF • ALK • MET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 03/17/2026","start_date":" 03/17/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2026-03-13"},{"id":"fd4f177e-f85d-440b-907a-20a6e87e3329","acronym":"PRO-ACTIVE","url":"https://clinicaltrials.gov/study/NCT07469709","created_at":"2026-03-28T01:44:12.315Z","updated_at":"2026-03-28T01:44:12.315Z","phase":"","brief_title":"A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks","source_id_and_acronym":"NCT07469709 - PRO-ACTIVE","lead_sponsor":"Fondazione del Piemonte per l'Oncologia","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"],"overall_status":"Recruiting","enrollment":" Enrollment 850","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2026-03-13"},{"id":"bedbd783-08c6-45af-8549-e837e9ef10ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT07198620","created_at":"2025-10-04T08:02:50.601Z","updated_at":"2025-10-04T08:02:50.601Z","phase":"","brief_title":"A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China","source_id_and_acronym":"NCT07198620","lead_sponsor":"Guangdong Association of Clinical Trials","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Dupert (fulzerasib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-09-30"},{"id":"ab44ad05-9bd9-4db7-9ebb-ab1b8496e06f","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190027","created_at":"2025-09-27T08:39:53.097Z","updated_at":"2025-09-27T08:39:53.097Z","phase":"Phase 1/2","brief_title":"Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial","source_id_and_acronym":"NCT07190027","lead_sponsor":"First Affiliated Hospital of Wenzhou Medical University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 246","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2025-09-24"},{"id":"b11c3dd5-a7d2-45b9-88bd-188586703589","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190248","created_at":"2025-09-27T08:39:58.068Z","updated_at":"2025-09-27T08:39:58.068Z","phase":"Phase 3","brief_title":"A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","source_id_and_acronym":"NCT07190248","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1 • KRAS","pipe":"","alterations":" ","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • calderasib (MK-1084)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 675","initiation":"Initiation: 10/27/2025","start_date":" 10/27/2025","primary_txt":" Primary completion: 12/07/2029","primary_completion_date":" 12/07/2029","study_txt":" Completion: 08/06/2032","study_completion_date":" 08/06/2032","last_update_posted":"2025-09-24"},{"id":"744cefa6-7afb-4f15-a0be-a9b48479230c","acronym":"SURGAN-ICI","url":"https://clinicaltrials.gov/study/NCT07177105","created_at":"2025-09-20T07:06:49.764Z","updated_at":"2025-09-20T07:06:49.764Z","phase":"Phase 2","brief_title":"Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC","source_id_and_acronym":"NCT07177105 - SURGAN-ICI","lead_sponsor":"Jianxing He","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Tyvyt (sintilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 09/10/2025","start_date":" 09/10/2025","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2030","study_completion_date":" 10/01/2030","last_update_posted":"2025-09-16"},{"id":"7ee22b9c-eea6-45ba-bdc2-0adfd9a6a3e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07174908","created_at":"2025-09-20T07:06:19.138Z","updated_at":"2025-09-20T07:06:19.138Z","phase":"Phase 3","brief_title":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","source_id_and_acronym":"NCT07174908","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed • Anfangning (garsorasib) • ifebemtinib (IN10018)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2025-09-16"},{"id":"9878563c-8961-4069-b799-4ed976e57f17","acronym":"RICEPS-2","url":"https://clinicaltrials.gov/study/NCT07163507","created_at":"2025-09-13T08:43:08.345Z","updated_at":"2025-09-13T08:43:08.345Z","phase":"","brief_title":"Immune Response Under Immunotherapy in Lung Cancer: Study of Sputum Samples","source_id_and_acronym":"NCT07163507 - RICEPS-2","lead_sponsor":"University Hospital, Tours","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-09-09"},{"id":"a6d31c69-7c36-43a0-bc25-c25fb37e0176","acronym":"AGA TKI NSCLC","url":"https://clinicaltrials.gov/study/NCT07158840","created_at":"2025-09-13T08:44:13.914Z","updated_at":"2025-09-13T08:44:13.914Z","phase":"Phase 2","brief_title":"AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment","source_id_and_acronym":"NCT07158840 - AGA TKI NSCLC","lead_sponsor":"Akeso","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/05/2025","start_date":" 09/05/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2025-09-08"},{"id":"27751dcd-f28f-4f36-b8db-e4042ae9fc77","acronym":"CVL006-T1002","url":"https://clinicaltrials.gov/study/NCT07157956","created_at":"2025-09-13T08:47:52.158Z","updated_at":"2025-09-13T08:47:52.158Z","phase":"Phase 1/2","brief_title":"CVL006 Combination Therapy in Advanced Solid Tumors","source_id_and_acronym":"NCT07157956 - CVL006-T1002","lead_sponsor":"Convalife (Shanghai) Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • Padcev (enfortumab vedotin-ejfv) • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 318","initiation":"Initiation: 09/10/2025","start_date":" 09/10/2025","primary_txt":" Primary completion: 08/12/2028","primary_completion_date":" 08/12/2028","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-09-05"},{"id":"25644c79-5dff-4f90-909f-44d8053dcbb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT07148128","created_at":"2025-08-30T13:47:31.239Z","updated_at":"2025-08-30T13:47:31.239Z","phase":"Phase 1/2","brief_title":"Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.","source_id_and_acronym":"NCT07148128","lead_sponsor":"Auricula Biosciences Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/28/2025","start_date":" 07/28/2025","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-08-29"},{"id":"716dc364-32b8-4cd4-ad8c-813b9359535b","acronym":"PB-PD1R-SCC","url":"https://clinicaltrials.gov/study/NCT07147361","created_at":"2025-09-07T01:05:27.471Z","updated_at":"2025-09-07T01:05:27.471Z","phase":"","brief_title":"Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma","source_id_and_acronym":"NCT07147361 - PB-PD1R-SCC","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2025-08-29"},{"id":"37fa384b-e7a2-4ce7-847c-4eaff8ded1d9","acronym":"SPRINT 2","url":"https://clinicaltrials.gov/study/NCT07146230","created_at":"2025-08-30T13:48:56.537Z","updated_at":"2025-08-30T13:48:56.537Z","phase":"Phase 2","brief_title":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","source_id_and_acronym":"NCT07146230 - SPRINT 2","lead_sponsor":"Montefiore Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-08-28"},{"id":"f4e7bfa0-b752-484d-96c0-7b0fd411e68b","acronym":"","url":"https://clinicaltrials.gov/study/NCT07144280","created_at":"2025-08-30T13:50:25.910Z","updated_at":"2025-08-30T13:50:25.910Z","phase":"Phase 3","brief_title":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT07144280","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • PF-08046054"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 680","initiation":"Initiation: 08/22/2025","start_date":" 08/22/2025","primary_txt":" Primary completion: 03/10/2028","primary_completion_date":" 03/10/2028","study_txt":" Completion: 03/10/2032","study_completion_date":" 03/10/2032","last_update_posted":"2025-08-27"},{"id":"ce310784-ab8d-4fcf-8c5f-3eb275e12f0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT07119190","created_at":"2025-08-16T14:07:27.150Z","updated_at":"2025-08-16T14:07:27.150Z","phase":"","brief_title":"A Perioperative Comprehensive Diagnosis and Treatment System for Lung Cancer in the Era of Neoadjuvant Immunotherapy","source_id_and_acronym":"NCT07119190","lead_sponsor":"Peking University People's Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 08/06/2025","start_date":" 08/06/2025","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 10/30/2027","study_completion_date":" 10/30/2027","last_update_posted":"2025-08-12"},{"id":"4d685c3c-c241-492e-8175-ba6e014943a8","acronym":"DeniLA","url":"https://clinicaltrials.gov/study/NCT07109154","created_at":"2025-08-09T14:25:42.572Z","updated_at":"2025-08-09T14:25:42.572Z","phase":"","brief_title":"DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns","source_id_and_acronym":"NCT07109154 - DeniLA","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/31/2025","start_date":" 07/31/2025","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-08-07"},{"id":"26cf9ebe-78e6-458c-aa63-ee9d1fa72ec1","acronym":"","url":"https://clinicaltrials.gov/study/NCT07096882","created_at":"2025-08-02T14:02:37.142Z","updated_at":"2025-08-02T14:02:37.142Z","phase":"Phase 1","brief_title":"SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection","source_id_and_acronym":"NCT07096882","lead_sponsor":"Cytocraft Biopharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 07/26/2025","start_date":" 07/26/2025","primary_txt":" Primary completion: 06/26/2027","primary_completion_date":" 06/26/2027","study_txt":" Completion: 06/26/2029","study_completion_date":" 06/26/2029","last_update_posted":"2025-07-31"},{"id":"70cc1b41-3bca-4660-a674-24287764e8ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT07094204","created_at":"2025-08-02T14:04:37.665Z","updated_at":"2025-08-02T14:04:37.665Z","phase":"Phase 1","brief_title":"A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors","source_id_and_acronym":"NCT07094204","lead_sponsor":"Astellas Pharma Inc","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 364","initiation":"Initiation: 07/31/2025","start_date":" 07/31/2025","primary_txt":" Primary completion: 11/30/2028","primary_completion_date":" 11/30/2028","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-07-30"},{"id":"bf382896-655a-44da-bab6-a9973e918517","acronym":"","url":"https://clinicaltrials.gov/study/NCT07082179","created_at":"2025-07-26T13:28:21.688Z","updated_at":"2025-07-26T13:28:21.688Z","phase":"Phase 2","brief_title":"A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer","source_id_and_acronym":"NCT07082179","lead_sponsor":"Jiangsu Cancer Institute \u0026 Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-07-24"},{"id":"6327dec6-05f5-4a23-9177-c88c3db8f2ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT06951399","created_at":"2025-07-26T13:31:06.459Z","updated_at":"2025-07-26T13:31:06.459Z","phase":"Phase 2","brief_title":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06951399","lead_sponsor":"Rabin Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2025-07-22"},{"id":"a24dd70d-457e-4bf3-b1b4-2106aa67a692","acronym":"","url":"https://clinicaltrials.gov/study/NCT07064018","created_at":"2025-07-19T14:18:32.626Z","updated_at":"2025-07-19T14:18:32.626Z","phase":"Phase 1/2","brief_title":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","source_id_and_acronym":"NCT07064018","lead_sponsor":"University of California, Irvine","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2031","study_completion_date":" 12/31/2031","last_update_posted":"2025-07-14"},{"id":"8260f352-f0e1-4ec2-80e3-a705d1b2d6be","acronym":"","url":"https://clinicaltrials.gov/study/NCT06980272","created_at":"2025-06-28T13:43:54.833Z","updated_at":"2025-06-28T13:43:54.833Z","phase":"Phase 3","brief_title":"SSGJ-707 in Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06980272","lead_sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 06/20/2025","start_date":" 06/20/2025","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-06-24"}]